Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
Bridge Biotherapeutics, a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announced it has received notice from the U.S.…
Read More...
Read More...
